A better understanding of human immunodeficiency virus type 1 drug-resistance evolution under the selective pressure of combination treatment is important for the design of long-term effective treatment strategies. We applied Bayesian network learning to sequences from patients treated with the reverse transcriptase inhibitor combination of zidovudine (AZT) and lamivudine (3TC) to identify the role of many treatment-selected mutations in the development of resistance. Based on the Bayesian network structure, an in vivo fitness landscape was built, reflecting the necessary selective pressure under treatment, to evolve naive sequences to sequences obtained from patients treated with the combination. This landscape, combined with an evolutionary model, was used to predict resistance evolution in longitudinal sequence pairs. In our analysis, mutations 41L, 70R, 184V and 215F/Y were identified as major resistance mutations to the combination of AZT and 3TC, as they were associated directly with treatment experience. The network also suggested a possible role in resistance development for a number of novel mutations. Estimated fitness, using the landscape, correlated significantly with in vitro resistance phenotype in genotype–phenotype pairs (R2=0.70). Variation in predicted evolution under selective pressure correlated significantly with observed in vivo evolution during AZT plus 3CT treatment. In conclusion, we confirmed current knowledge on resistance development to the combination of AZT and 3CT, but additional novel mutations were identified. Moreover, a model to predict resistance evolution during AZT and 3CT treatment has been built and validated.
BeerenwinkelN.,
SingT.,
LengauerT.,
RahnenführerJ.,
RoompK.,
SavenkovI.,
FischerR.,
HoffmannD.,
Selbig, J. & other authors.
2005a; Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21:3943–3950
BeerenwinkelN.,
DäumerM.,
SingT.,
RahnenführerJ.,
LengauerT.,
SelbigJ.,
HoffmannD.,
KaiserR.2005b; Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 191:1953–1960
BennettD. E.,
CamachoR. J.,
OteleaD.,
KuritzkesD. R.,
FleuryF.,
KiuchiM.,
HeneineW.,
KantorR.,
JordanM. R.other authors2009; Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4:e4724
BoucherC. A.,
O'SullivanE.,
MulderJ. W.,
RamautarsingC.,
KellamP.,
DarbyG.,
LangeJ. M.,
GoudsmitJ.,
LarderB. A.1992; Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 165:105–110
BoucherC. A.,
CammackN.,
SchipperP.,
SchuurmanR.,
RouseP.,
WainbergM. A.,
CameronJ. M.1993; High-level resistance to (−) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 37:2231–2234
Ceccherini-SilbersteinF.,
SvicherV.,
SingT.,
ArteseA.,
SantoroM. M.,
ForbiciF.,
BertoliA.,
AlcaroS.,
PalamaraG.other authors2007; Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 81:11507–11519
Cozzi-LepriA.,
RuizL.,
LovedayC.,
PhillipsA. N.,
ClotetB.,
ReissP.,
LedergerberB.,
HolkmannC.,
StaszewskiS.other authors2005; Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10:791–802
DeforcheK.,
SilanderT.,
CamachoR. J.,
GrossmanZ.,
SoaresM. A.,
Van LaethemK.,
KantorR.,
MoreauY.,
VandammeA.-M.other authors2006; Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics 22:2975–2979
DeforcheK.,
CamachoR. J.,
Van LaethemK.,
ShapiroB.,
MoreauY.,
RambautA.,
VandammeA.-M.,
LemeyP.2007b; Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo . J Comput Biol 14:1105–1114
DeforcheK.,
CamachoR. J.,
GrossmanZ.,
SoaresM. A.,
Van LaethemK.,
KatzensteinD. A.,
HarriganP. R.,
KantorR.,
ShaferR. W.other authors2008a; Bayesian network analyses of resistance pathways against efavirenz and nevirapine. AIDS 22:2107–2115
DeforcheK.,
CamachoR. J.,
Van LaethemK.,
LemeyP.,
RambautA.,
MoreauY.,
VandammeA. M.2008b; Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment. Bioinformatics 24:34–41
DeforcheK.,
Cozzi-LepriA.,
TheysK.,
ClotetB.,
CamachoR. J.,
KjaerJ.,
Van LaethemK.,
PhillipsA. N.,
MoreauY. & other authors (2008c). Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther 13:399–407
de OliveiraT.,
DeforcheK.,
CassolS.,
SalminenM.,
ParaskevisD.,
SeebregtsC.,
SnoeckJ.,
van RensburgE. J.,
WensingA. M. J.other authors2005; An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21:3797–3800
JohnsonV. A.,
Brun-VezinetF.,
ClotetB.,
GunthardH. F.,
KuritzkesD. R.,
PillayD.,
SchapiroJ. M.,
RichmanD. D.2008; Update of the drug resistance mutations in HIV-1. Top HIV Med 16:138–145
KantorR.,
MachekanoR.,
GonzalesM. J.,
DupnikK.,
SchapiroJ. M.,
ShaferR. W.2001; Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language and sequence analysis programs. Nucleic Acids Res 29:296–299
MillerV.,
PhillipsA.,
RottmannC.,
StaszewskiS.,
PauwelsR.,
HertogsK.,
de BthuneM. P.,
KempS. D.other authors1998; Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 177:1521–1532
MyllymäkiP.,
SilanderT.,
TirriH.,
UronenP.2002; B-Course: a web-based tutorial for Bayesian and causal data analysis. Int J Artif Intell Tools 11:396–387
PearlJ.1988Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference San Mateo, CA: Morgan Kaufmann;
RheeS. Y.,
FesselJ. W.,
ZolopaA. R.,
HurleyL.,
LiuT.,
TaylorJ.,
NguyenD. P.,
SlomeS.,
KleinD.other authors2005; HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 192:456–465
ShaferR. W.,
IversenA. K.,
WintersM. A.,
AguinigaE.,
KatzensteinD. A.,
MeriganT. C.1995; Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 172:70–78
SturmerM.,
StaszewskiS.,
DoerrH. W.,
LarderB.,
BloorS.,
HertogsK.2003; Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214. Antimicrob Agents Chemother 47:54–61
SvicherV.,
SingT.,
SantoroM. M.,
ForbiciF.,
Rodríguez-BarriosF.,
BertoliA.,
BeerenwinkelN.,
BellocchiM. C.,
GagoF.other authors2006; Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 80:7186–7198
Van VaerenberghK.,
Van LaethemK.,
AlbertJ.,
BoucherC. A.,
ClotetB.,
FloridiaM.,
GerstoftJ.,
HejdemanB.,
NielsenC.other authors2000; Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 44:2109–2117
VingerhoetsJ.,
AzijnH.,
FransenE.,
De BaereI.,
SmeuldersL.,
JochmansD.,
AndriesK.,
PauwelsR.,
de BethuneM. P.2005; TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 79:12773–12782
WainbergM. A.,
BrennerB. G.,
TurnerD.2005; Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 49:1671–1678